In vitro metabolism study of ADB‐P‐5Br‐INACA and ADB‐4en‐P‐5Br‐INACA using human hepatocytes, liver microsomes, and in‐house synthesized references

Abstract

AbstractSynthetic cannabinoids (SCs) remain a major public health concern, as they continuously are linked to severe intoxications and drug‐related deaths worldwide. As new SCs continue to emerge on the illicit drug market, an understanding of SC metabolism is needed to identify formed metabolites that may serve as biomarkers in forensic toxicology screening and for understanding the pharmacokinetics of the drugs. In this work, the metabolism of ADB‐4en‐P‐5Br‐INACA and ADB‐P‐5Br‐INACA ((S)‐N‐(1‐amino‐3,3‐dimethyl‐1‐oxobutan‐2‐yl)‐5‐bromo‐1‐(pent‐4‐en‐1‐yl)‐1H‐indazole‐3‐carboxamide, (S)‐N‐(1‐amino‐3,3‐dimethyl‐1‐oxobutan‐2‐yl)‐5‐bromo‐1‐pentyl‐1H‐indazole‐3‐carboxamide respectively) were investigated using human hepatocytes in vitro and in‐house synthesized references. Both SCs were incubated with pooled human hepatocytes over 3 h, with the aim to identify unique and abundant metabolites using liquid chromatography–quadrupole time‐of‐flight mass spectrometry (LC‐QTOF‐MS). In total nine metabolites were identified for ADB‐4en‐P‐5Br‐INACA and 10 metabolites for ADB‐P‐5Br‐INACA. The observed biotransformations included dihydrodiol formation, terminal amide hydrolysis, hydroxylation, dehydrogenation, carbonyl formation, glucuronidation, and combinations thereof. The major metabolites were confirmed by in‐house synthesized references. Recommended biomarkers for ADB‐P‐5Br‐INACA and ADB‐4en‐P‐5Br‐INACA are the terminal hydroxy and dihydrodiol metabolite respectively.